Researchers at UCLA have found that creatine, commonly used by athletes, may enhance the immune system’s ability to combat cancer by boosting both killer T cells and dendritic cells. This new study, published in iScience, indicates that creatine not only invigorates T cells, which destroy cancer cells, but also strengthens dendritic cells, which play a crucial role in activating T cells against tumors.
Key Findings:
- Enhanced Immune Response: The study revealed that creatine supports dendritic cells in better preparing T cells for a cancer attack. This could improve immunotherapy effectiveness for more patients, as current immunotherapies benefit only a fraction of patients.
- Energy Supply: Creatine supplementation in mouse models led to increased ATP levels in dendritic cells, providing the necessary energy for their functions and maintaining inflammatory signals needed for activation.
- Human Relevance: Experiments with human-derived dendritic cells indicated that creatine improved their activation and ability to stimulate T cells against cancer targets, suggesting creatine could enhance dendritic cell-based vaccines.
Future Directions:
The researchers emphasize the need for clinical trials to evaluate creatine’s impact on cancer treatment in patients. Although creatine is generally recognized as safe, individuals undergoing cancer treatment should consult their doctors before using any supplements.
In conclusion, this study highlights the potential of creatine as a dual strategy: as a supplement to boost immune responses in patients receiving immunotherapy and to improve the production of effective dendritic cell vaccines.
